Early NBTXR3 Trial Data in Esophageal Cancer Show 85% Disease Control Rate and Feasible Injection Approach

Study Finds High Response Rates and Tolerability in Challenging Patient Group

Newly released Phase 1 data from Nanobiotix’s JNJ-1900 (NBTXR3) clinical trial mark a significant development for patients with locally advanced esophageal adenocarcinoma. In the first two dose escalation cohorts, researchers found that endoscopic injection of NBTXR3 combined with chemoradiation not only proved feasible in all 13 treated patients but also delivered an impressive 85% disease control rate and a 69% objective response rate—including six complete and three partial responses.

Treatment Protocol Well-Tolerated with Confirmed Safety Profile

The safety data is especially notable. All participants (n=13) experienced some form of treatment-emergent adverse event, yet only two experienced more severe (grade 3+) events attributable to NBTXR3. There were no severe events tied to the injection itself, and no periprocedural or delayed adverse effects were observed. The recommended Phase 2 dose was established at 33% of the gross tumor volume (GTV).

Why These Results Matter: Clinical Context and Implications

Esophageal cancer remains among the most difficult to treat, often requiring highly invasive surgeries like esophagectomy, which can lead to substantial comorbidities and affect quality of life. The robust control and response rates observed with NBTXR3, alongside its tolerability, raise hopes for therapies that may help avoid or lessen the extent of surgical intervention. As principal investigator Dr. Steven Lin noted, these results suggest that local tumor control can be enhanced while potentially sparing patients from some of the most challenging surgical risks.

Recruitment Ongoing as Study Seeks to Expand Efficacy Evidence

The current analysis stems from the dose escalation phase, with 17 more patients slated for inclusion as part of the ongoing study expansion. Importantly, this trial may pave the way for a new indication for NBTXR3—not only with standard photon radiation but also as a radioenhancer for proton radiation therapy, broadening its clinical potential.

Next Steps for NBTXR3: From Proof-of-Concept to Broader Solid Tumor Trials

NBTXR3 is built on a physics-based mechanism, using hafnium oxide nanoparticles that, when injected and activated by radiotherapy, induce significant tumor cell death and potentially trigger longer-term anti-cancer immunity. The ongoing NANORAY-312 study in head and neck cancers and various collaborative trials with MD Anderson and Janssen underline its scalability and strategic significance.

What Should Investors and Patients Watch Next?

While these results are still early and part of a Phase 1 study, they deliver a compelling signal for the feasibility and potential efficacy of NBTXR3 in hard-to-treat cancers. Ongoing and future expansions will be critical to confirming its promise—especially regarding reduced surgical needs and long-term outcomes. For now, both clinicians and stakeholders will be watching as Nanobiotix continues to expand patient recruitment and pushes this novel therapy toward more definitive trials.

Contact:
Nanobiotix Investor Relations (US): investors@nanobiotix.com
Nanobiotix Investor Relations (EU): investors@nanobiotix.com

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI